AI Engines For more Details: Perplexity Kagi Labs You
Growth Promotion: The primary intended effect of MGA in livestock is to promote weight gain and improve feed efficiency. By acting as a synthetic progestin, MGA can alter the hormonal balance in animals, leading to increased appetite and enhanced nutrient utilization, which ultimately results in accelerated growth rates.
Reproductive Effects: In female animals, MGA can exert contraceptive effects by inhibiting ovulation and disrupting normal estrous cycling. This property is often utilized in beef cattle production to suppress estrus in feedlot heifers, allowing for more efficient weight gain and improved carcass quality. However, prolonged exposure to MGA may disrupt reproductive function and fertility in livestock.
Hormonal Disruption: MGA belongs to the class of compounds known as endocrine disruptors, which have the potential to interfere with hormonal signaling pathways in animals. Chronic exposure to MGA may disrupt the normal functioning of the endocrine system, leading to various adverse effects on metabolism, growth, and reproductive health.
Residue Concerns: The use of MGA in livestock production raises concerns about the presence of residues in meat products intended for human consumption. While regulatory agencies establish maximum residue limits (MRLs) for MGA in food products, there is ongoing debate about the potential health risks associated with long-term exposure to low levels of MGA residues in meat.
Environmental Contamination: MGA, like other veterinary drugs, can enter the environment through the excretion of treated animals and the disposal of manure. There is potential for MGA residues to contaminate soil, water, and vegetation, posing risks to non-target organisms and ecosystems.
Antibiotic Combination Products: In some cases, MGA is formulated in combination with antibiotics (e.g., MGA/Terramycin). The use of antibiotic combination products raises additional concerns about antimicrobial resistance and the potential for the development of drug-resistant bacteria.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 0.9 | 0.6 | 0.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 2 | 0 | 0 |
| Allergies | 2.3 | 0.9 | 1.56 |
| Allergy to milk products | 0.8 | 1.3 | -0.63 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 2.5 | 2.6 | -0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0 | 0 |
| Ankylosing spondylitis | 1.8 | 0.8 | 1.25 |
| Anorexia Nervosa | 0.6 | 0.7 | -0.17 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 1.1 | 0.3 | 2.67 |
| Atherosclerosis | 0.5 | 0.6 | -0.2 |
| Atrial fibrillation | 1.2 | 2 | -0.67 |
| Autism | 4.2 | 3.7 | 0.14 |
| Autoimmune Disease | 0.6 | 0.2 | 2 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 2.1 | 0.6 | 2.5 |
| Brain Trauma | 0.3 | -0.3 | |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 1.9 | 0.7 | 1.71 |
| Celiac Disease | 0.9 | 1 | -0.11 |
| Cerebral Palsy | 0.5 | 0.3 | 0.67 |
| Chronic Fatigue Syndrome | 2.1 | 2.9 | -0.38 |
| Chronic Kidney Disease | 2.5 | 0.6 | 3.17 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0.8 | 0.6 | 0.33 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 1.1 | |
| Cognitive Function | 0.7 | 0.2 | 2.5 |
| Colorectal Cancer | 2.8 | 0.8 | 2.5 |
| Constipation | 1.3 | 1.3 | |
| Coronary artery disease | 1.2 | 0.8 | 0.5 |
| COVID-19 | 3.6 | 3.5 | 0.03 |
| Crohn's Disease | 4.1 | 1.2 | 2.42 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 0.6 | 0.3 | 1 |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 1.1 | 0.3 | 2.67 |
| Depression | 4.3 | 2.5 | 0.72 |
| Eczema | 1.3 | 0.4 | 2.25 |
| Endometriosis | 1.6 | 0.3 | 4.33 |
| Epilepsy | 1.4 | 0.8 | 0.75 |
| erectile dysfunction | 2 | 2 | |
| Fibromyalgia | 1.4 | 1.5 | -0.07 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 2.2 | 0.32 |
| gallstone disease (gsd) | 2 | 2 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.6 | |
| Generalized anxiety disorder | 2 | 0.8 | 1.5 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1.3 | 0.5 | 1.6 |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.5 | 0.3 | 0.67 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.5 | 0.6 | -0.2 |
| Heart Failure | 2.4 | 2.4 | |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.6 | 0.7 | -0.17 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.4 | 1.2 | 0.17 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 1.8 | 0.4 | 3.5 |
| IgA nephropathy (IgAN) | 1 | 1.7 | -0.7 |
| Inflammatory Bowel Disease | 4.6 | 2.6 | 0.77 |
| Insomnia | 0.6 | 0.3 | 1 |
| Intelligence | 0.8 | 0.4 | 1 |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 2.3 | 2.1 | 0.1 |
| ischemic stroke | 0.8 | 0.9 | -0.13 |
| Liver Cirrhosis | 2.6 | 1.1 | 1.36 |
| Long COVID | 4 | 1.4 | 1.86 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 1.2 | 1.2 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.3 | 1 |
| ME/CFS with IBS | 0.2 | 0.9 | -3.5 |
| ME/CFS without IBS | 1.4 | 0.8 | 0.75 |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 4.2 | 2.1 | 1 |
| Mood Disorders | 4.1 | 2.7 | 0.52 |
| Multiple Sclerosis | 2.8 | 2.6 | 0.08 |
| myasthenia gravis | 0.6 | 0.2 | 2 |
| neuropathic pain | 0.3 | 0.7 | -1.33 |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 0.6 | 3 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 3.9 | 2.2 | 0.77 |
| obsessive-compulsive disorder | 2.4 | 1.5 | 0.6 |
| Osteoarthritis | 2 | 0.3 | 5.67 |
| Osteoporosis | 1.4 | 0.3 | 3.67 |
| Parkinson's Disease | 2.6 | 2.4 | 0.08 |
| Polycystic ovary syndrome | 3.5 | 0.8 | 3.38 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Primary sclerosing cholangitis | 0.9 | 2 | -1.22 |
| Psoriasis | 0.5 | 1.9 | -2.8 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1 | 2.1 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 2 | 1.2 | 0.67 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 1.4 | 0.7 | 1 |
| Sleep Apnea | 0.3 | 0.9 | -2 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1 | 1.4 | -0.4 |
| Systemic Lupus Erythematosus | 3.1 | 3.1 | |
| Tic Disorder | 0.4 | 0.4 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 2.7 | 0.9 | 2 |
| Type 2 Diabetes | 4 | 2 | 1 |
| Ulcerative colitis | 2.8 | 3 | -0.07 |
| Unhealthy Ageing | 2.3 | 0.7 | 2.29 |
| Vitiligo | 0.9 | 1.2 | -0.33 |
